Highlights third quarter 2025:
o Q3 revenue reached USD 56.8 million, a 15% increase year-over-year, with
adjusted EBITDA of USD 12.2 million, up 50% from the prior year.
o Human Health Ingredients delivered USD 30.2 million in revenue, up 23% YoY,
driven by solid volume growth and improved price mix. Adjusted EBITDA grew 35%
to USD 13.5 million.
o Consumer Health Products generated USD 27.4 million in revenue, down 6% YoY,
with stable EBITDA margins.
o Emerging Business reported USD 2.0 million in revenue, stable compared to
previous quarters. EBITDA improved from last year on lower opex.
o Secured significant new business for the supply of Superba Krill Oil.

"We continued our strong momentum in the third quarter, with 15% revenue growth
and a 50% increase in adjusted EBITDA year-over-year. Human Health Ingredients
again delivered good results, with strong demand across regions. Our ability to
win new business further strengthens the outlook for this segment," said Matts
Johansen, CEO of Aker BioMarine.

Segment performance
Human Health Ingredients continued its strong trajectory with 23% revenue growth
year-over-year, driven by both higher volumes and improved price mix. Adjusted
EBITDA increased significantly, supported by solid gross margins and good
operational leverage. During the quarter, the company secured a significant new
supply agreement for Superba Krill Oil.

Consumer Health Products reported a 6% decline in revenue year-over-year, mainly
due to lower demand from drug stores. Demand has remained stable throughout
2025, albeit below the strong levels in the second half of 2024. EBITDA margin
remained stable compared to last year as lower revenues was offset by improved
gross margin. 

Outlook
The Human Health Ingredients segment sees continued year-over-year growth,
supported by good underlying demand in multiple markets. In Consumer Health
Products, revenues are expected to follow market growth over time. The Emerging
Business segment remains on track toward cash break-even, with active engagement
in potential transactions. At the corporate level, the company has established a
new, leaner cost base and is executing on initiatives to further improve
financial and operational efficiency. 

AKBM is adapting to market trends through productivity and cost measures while
actively assessing the potential impact of increased macroeconomic uncertainty
and new tariffs.

Attached is the quarterly presentation and report for Q3. Group reported
financial figures can be downloaded in an excel from the company's investor
page: Investor - Analyst information

At 09:00 CET today, the management hosts a webcast. The webcasted presentation
will be in English. To join, please use the link that is available at
www.akerbiomarine.com/investor. 

A replay of the presentation will be made available soon after the presentation
at the same web address.

For further information, please contact 
Christopher Robin Vinter, VP Strategic Finance & IR 
Mobile: +47 911 60 820 
Email: Christopher.vinter@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.